UroGen Pharma Ltd.

Contributing Author

Recent Articles by UroGen Pharma Ltd.

May-15	UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC URGN GlobeNewswire
May-13	ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial URGN GlobeNewswire
May-07	UroGen Pharma to Present at Upcoming Investor Conferences URGN GlobeNewswire
May-06	UroGen Reports ZUSDURI Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights URGN +10.16% GlobeNewswire
Apr-29	UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026 URGN GlobeNewswire
Apr-08	UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer URGN +5.93% GlobeNewswire
Mar-30	Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI URGN GlobeNewswire
Mar-13	UroGen Applauds BCAN's New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence URGN GlobeNewswire
Mar-06	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) URGN GlobeNewswire
Mar-02	UroGen Announces ZUSDURI Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results URGN -12.35% GlobeNewswire
Mar-02	UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors URGN -12.35% GlobeNewswire
Feb-27	ZUSDURI Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC URGN GlobeNewswire
Feb-24	UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference URGN GlobeNewswire
Feb-23	UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026 URGN GlobeNewswire
Feb-04	UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit URGN GlobeNewswire
Jan-05	Permanent J Code for ZUSDURI Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy URGN GlobeNewswire
Dec-05	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) URGN -5.35% GlobeNewswire
Nov-25	UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference URGN GlobeNewswire
Nov-06	UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI Launch Gains Momentum URGN +21.91% GlobeNewswire
Nov-06	UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial URGN +21.91% GlobeNewswire
Nov-04	UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference URGN GlobeNewswire
Oct-30	UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025 URGN GlobeNewswire
Oct-27	Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI Effective January 1, 2026 URGN +9.91% GlobeNewswire
Oct-02	ZUSDURI Clinical Review Published in Reviews in Urology Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer URGN GlobeNewswire
Sep-08	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) URGN +13.45% GlobeNewswire
Aug-21	UroGen Pharma to Present at Upcoming Investor Conferences URGN GlobeNewswire
Aug-07	UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI and Reports Second Quarter 2025 Financial Results URGN -7.10% GlobeNewswire
Aug-05	UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer URGN GlobeNewswire
Jul-29	UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025 URGN GlobeNewswire
Jul-28	UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology URGN GlobeNewswire
Jul-21	UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer URGN GlobeNewswire
Jul-07	UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer URGN GlobeNewswire

UroGen Pharma Ltd.

Recent Articles by UroGen Pharma Ltd.

Upgrade your Finviz experience